Antithrombotic Therapy in Prevention of Ischemic Stroke
Series: Oxford American Pocket Notes;
- Publisher's listprice GBP 12.99
-
6 205 Ft (5 910 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 10% (cc. 621 Ft off)
- Discounted price 5 585 Ft (5 319 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
6 205 Ft
Availability
Out of print
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher OUP USA
- Date of Publication 19 August 2010
- ISBN 9780195394320
- Binding Spiral bound
- No. of pages56 pages
- Size 173x94x3 mm
- Weight 60 g
- Language English 0
Categories
Short description:
Part of the Oxford American Pocket Note series, this book provides the clinician wtih up-to-date information on the guidelines and therapeutic options in recurrent stroke/TIA prevention. Treatment algorithms, illustrations, medication tables, charts, and figures enable both the specialist and the primary provider to ensure the best care for their patients in order to prevent the reocurrence of stroke/TIA.
MoreLong description:
Stroke is the most common cause of adult mortality in the United States. Antithrombotic agents form the mainstay of stroke prevention. Aspirin produces a modest reduction in the risk of second stroke and transient ischemic attack (TIA, mini-stroke) and is widely recommended for initial therapy. The thienopyridines (Ticlid) and clopodogrel (Plavix) are alternatives for secondary prevention in patients who do not respond to or cannot take aspirin. They are no more
effective than aspirin and have been associated with thrombotic thrombocytopenic purpura. The combination of aspirin and extended-release dipyridamole (Aggrenox) has several mechanisms of action and an additive effect on reducing stroke risk compared with either agent alone. A 2-fold increase in risk
reduction and favorable safety profile suggest that the combination can serve as first-line prophylaxis against a second stroke. This volume, as part of the Oxford American Pocket Note series, provides the clinician with up-to-date information on the guidelines, and therapeutic options in recurrent stroke/TIA prevention. Useful features include treatment algorithms, illustrations, medication tables, charts and figures to enable both the specialist and the primary provider to ensure the
best options to their patients in order to prevent the reocurrence of stroke/TIA.
Table of Contents:
Introduction and Epidemiology
Pathophysiology
Managing Risk Factors for Recurrent Stroke
Pharmacological Treatment Options
Non-pharmacological Treatment Options
Treatment Guidelines
Clinician and Patient Resources
